+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tyvaso"

Pulmonary Hypertension Associated with Interstitial Lung Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Pulmonary Hypertension Associated with Interstitial Lung Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 134 Pages
  • Global
From
Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report by Drug Class (Diuretics, ACE Inhibitors), Type (Primary, Secondary), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Thumbnail Image

Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report by Drug Class (Diuretics, ACE Inhibitors), Type (Primary, Secondary), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • December 2023
  • 180 Pages
  • Global
From
Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report by Drug Class, by Type (Branded, Generics), by Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), by Region, and Segment Forecasts, 2022-2030 - Product Thumbnail Image

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report by Drug Class, by Type (Branded, Generics), by Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), by Region, and Segment Forecasts, 2022-2030

  • Report
  • January 2022
  • 150 Pages
  • Global
From
North America Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel - Product Thumbnail Image

North America Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel

  • Report
  • February 2023
  • 143 Pages
  • North America
From
Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • January 2024
  • 250 Pages
  • Global
From
TYVASO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

TYVASO Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Disease Analysis: Pulmonary Hypertension - Product Thumbnail Image

Disease Analysis: Pulmonary Hypertension

  • Drug Pipelines
  • April 2021
  • 78 Pages
  • Global
Tyvaso - Product Thumbnail Image

Tyvaso

  • Report
  • October 2018
  • 17 Pages
  • Global
From
Tyvaso - API Insight, 2022 - Product Thumbnail Image

Tyvaso - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
  • 9 Results (Page 1 of 1)
Loading Indicator

Tyvaso is a brand of cardiovascular drug used to treat pulmonary arterial hypertension (PAH). It is a vasodilator, meaning it relaxes the blood vessels in the lungs, allowing for improved blood flow and oxygen delivery. Tyvaso is administered through an inhaler, and is typically used in combination with other PAH treatments. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of PAH in adults. The Tyvaso market is composed of pharmaceutical companies that manufacture and distribute the drug. These companies are responsible for the research, development, and marketing of the drug, as well as its distribution to healthcare providers. Additionally, they are responsible for ensuring the safety and efficacy of the drug. Some companies in the Tyvaso market include United Therapeutics Corporation, GlaxoSmithKline, and Novartis. Show Less Read more